All Stories

  1. The Contribution of Cerebral Vascular Neuropathology to Mild Stage of Alzheimer’s Dementia Using the NACC Database
  2. Contributions to dementia research by Australian Psychiatry
  3. Association of SORL1 Gene Variants with Hippocampal and Cerebral Atrophy and Alzheimer’s Disease
  4. Psychological well-being in individuals with mild cognitive impairment
  5. Psychiatric consequences of small vessel disease
  6. The contributions of twin studies to the understanding of brain ageing and neurocognitive disorders
  7. Glutamate in the Pathogenesis of Gliomas
  8. Drug Treatments for Alzheimer’s Disease: Hopes and Challenges
  9. Ionotropic Receptors in the Central Nervous System and Neurodegenerative Disease
  10. Spatial False Discovery Rate Control for Magnetic Resonance Imaging Studies
  11. P3–157: COSMIC: COhort Studies of Memory in an International Consortium
  12. P3–163: Dietary minerals and risk of MCI
  13. P1–241: Plasma protein profiling of mild cognitive impairment and Alzheimer's disease
  14. IC‐P‐097: The subclassifcation of amnestic MCI using MRI‐based cortical thickness measures
  15. P2–155: The subclassification of amnestic MCI using MRI‐based cortical thickness measures
  16. P4–327: MAPT methylation and implications for late‐onset Alzheimer's disease
  17. P3–088: Staging of microstructural white matter damage in early Alzheimer's disease
  18. P4–332: γ‐glutamylcysteine (GGC)‐mediated upregulation of glutathione levels can ameliorate toxicity of natural beta‐amyloid oligomers in primary adult human neurons
  19. P2–035: Development of a targeted mass spectrometry method for accurate quantification of human sirtuins in biological samples
  20. Dementia in the oldest old
  21. Neuroplasticity in Depressed Individuals Compared with Healthy Controls
  22. Psychiatry looks towards the future in neurodegenerative and neurodevelopmental disorders
  23. Is Alzheimer's a disease of the white matter?
  24. The Sydney Centenarian Study: methodology and profile of centenarians and near-centenarians
  25. Basic treatment principles for psychotic disorders in patients with epilepsy
  26. Age-Specific Effects of Voluntary Exercise on Memory and the Older Brain
  27. The Brain Effects of Laser Acupuncture in Depressed Individuals: An fMRI Investigation
  28. Hippocampal and amygdala volumes in an older bipolar disorder sample
  29. Deep Brain Stimulation of Anteromedial Globus Pallidus Interna for Severe Tourette's Syndrome
  30. F5‐02‐01: A critique of the extant criteria for vascular cognitive disorders and a proposal
  31. Sirtuins in cognitive ageing and Alzheimer's disease
  32. Alginate Microcapsule as a 3D Platform for Propagation and Differentiation of Human Embryonic Stem Cells (hESC) to Different Lineages
  33. A Review of Tobacco, Alcohol, Adiposity, and Activity as Predictors of Cognitive Change
  34. White Matter Hyperintensities Are an Independent Predictor of Physical Decline in Community-Dwelling Older People
  35. Cognitive and memory training in adults at risk of dementia: A Systematic Review
  36. The Genetics of White Matter Lesions
  37. Textbook of stroke medicine - M Brainin, W-D Heiss (Eds), Cambridge, UK, Cambridge University Press, 2010. Hardback: 326. ISBN: 978-0-521-51826-0.
  38. The paradox of psychosurgery to treat mental disorders
  39. P1‐434: Is age‐related variance in episodic memory mediated by processing speed or executive function?
  40. O4‐01‐02: Mild cogitive impairment in the 60s
  41. P4‐335: Genome‐wide association study of white matter lesions in older individuals
  42. P4‐365: Posterior compensatory network mediates spatial working memory in those with proficient cognition despite hippocampal atrophy
  43. P4‐443: Cell therapy plus voluntary running rescues memory dysfunction in a rodent model of brain ageing
  44. P3‐075: Mild cognitive impairment in older Australians from non‐English speaking backgrounds
  45. P1‐115: Plasma apolipoproteins as biomarkers of mild cognitive impairment in a community‐based sample
  46. P4‐124: Abnormal connectivity of the hippocampus in amnestic mild cognitive impairment: A diffusion tensor tractography study
  47. The narrative in neurology and psychiatry
  48. Structural brain networks and neuropsychiatric disorders
  49. Brain dysfunction in anorexia nervosa: cause or consequence of under-nutrition?
  50. Lifetime cigarette smoking is associated with striatal volume measures
  51. Homocysteine and Alzheimer disease: an intervention study
  52. The twilight of dementia
  53. Effect of age on proliferation‐regulating factors in human adult neurogenic regions
  54. Genetic influences on cognitive functions in the elderly: A selective review of twin studies
  55. A longitudinal study examining the independence of apathy and depression after stroke: the Sydney Stroke Study
  56. Computer-delivered cognitive behavioural therapy: effective and getting ready for dissemination
  57. FT‐01‐01: DSM‐V neurocognitive disorders cluster: General principles
  58. P3‐151: Change in adiposity measures and cognition in Australian aging women
  59. P3‐249: Meta‐analysis of plasma amyloid beta levels using cross‐sectional and longitudinal studies of Alzheimer's disease and dementia
  60. P3‐264: Modifiable risk factors for dementia interact with APOE and sex to predict hippocampal atrophy
  61. Under diagnosis of canine cognitive dysfunction: A cross-sectional survey of older companion dogs
  62. Faculty Opinions recommendation of Computer-aided psychotherapy for anxiety disorders: a meta-analytic review.
  63. Depersonalization disorder
  64. Magnetoencephalography in neuropsychiatry: ready for application?
  65. Secondary Schizophrenia
  66. The concept of organicity and its application to schizophrenia
  67. Huntington's Disease and related disorders and their association with schizophrenia-like psychosis
  68. Normal pressure hydrocephalus
  69. Schizophrenia secondary to cannabis use
  70. Toxic psychosis
  71. Storage disorders and psychosis
  72. Mitochondrial disorders and psychosis
  73. Brain tumors
  74. Demyelinating disease and psychosis
  75. Infection and schizophrenia
  76. The status of genetic investigations of schizophrenia
  77. Fahr's Disease and psychosis
  78. The Charles Bonnet Syndrome
  79. Acute brief psychosis – an organic syndrome?
  80. Neurobiology and etiology of primary schizophrenia: current status
  81. Secondary hallucinations
  82. Functional neuroimaging in schizophrenia
  83. The neurologic examination in schizophrenia
  84. Understanding the pathophysiology of schizophrenia through the looking glass of forced normalization
  85. Substance-induced psychosis: an overview
  86. Stimulants and psychosis
  87. Psychotomimetic effects of PCP, LSD, and Ecstasy: pharmacological models of schizophrenia?
  88. Cerebrovascular disease and psychosis
  89. Neurodegenerative disorders (Alzheimer's Disease, fronto-temporal dementia) and schizophrenia-like psychosis
  90. Psychosis associated with leukodystrophies
  91. Velocardiofacial syndrome (chromosome 22q11.2 deletion syndrome) as a model of schizophrenia
  92. Psychosis in Prader-Willi Syndrome
  93. Nonpharmacological interventions in secondary schizophrenia
  94. Core Curriculum in Neuropsychiatry of the International Neuropsychiatric Association*
  95. Do people become more apathetic as they grow older? A longitudinal study in healthy individuals
  96. Transcranial Direct Current Stimulation Priming of Therapeutic Repetitive Transcranial Magnetic Stimulation
  97. Behavioral and psychological symptoms associated with dementia subtype and severity
  98. The determinants and longitudinal course of post-stroke mild cognitive impairment
  99. Plasma biomarkers for mild cognitive impairment and Alzheimer's disease
  100. Conversion to mild cognitive impairment: Predictors in a large longitudinal study of ageing
  101. Who does well after a stroke? The Sydney Stroke Study
  102. Transcranial direct current stimulation - what is the evidence for its efficacy and safety?
  103. O4‐04‐05: Can cognitive training prevent the onset of dementia? A systematic review of randomized clinical trials with longitudinal follow up
  104. Neuroleptic Malignant Syndrome Associated with Atypical Antipsychotic Drugs
  105. Akathisia and second-generation antipsychotic drugs
  106. Neurosurgical treatment of mood disorders: traditional psychosurgery and the advent of deep brain stimulation
  107. Use of medications with anticholinergic properties and cognitive function in a young‐old community sample
  108. Repetitive transcranial magnetic stimulation as treatment for anxiety disorders
  109. Neuropsychiatry
  110. Brains of anorexia nervosa patients process self-images differently from non-self-images: An fMRI study
  111. O2‐01–05: Ubiquity and utility of subjective cognitive complaints
  112. P1‐004: Towards a data‐based diagnosis of canine cognitive dysfunction as an ecological model for Alzheimer's disease
  113. P1‐286: Diffusion tensor imaging as a biomarker of mild cognitive impairment
  114. P1‐337: Incidental lacunar infarcts, brain atrophy and white matter hyperintensities in a community population: The path through life study
  115. IC‐02‐03: Lifespan mental activity predicts diminished rate of hippocampal atrophy
  116. IC‐P3‐210: White matter hyperintensities are related to cognitive and motor function in middle‐aged healthy individuals
  117. White matter hyperintensities in mid-adult life
  118. Genetic and environmental influences on obsessive-compulsive disorder
  119. Treatment-Resistant Depression: Critique of Current Approaches
  120. Memory and executive functioning in obsessive–compulsive disorder: A selective review
  121. Complex mental activity and the aging brain: Molecular, cellular and cortical network mechanisms
  122. Increased Anterior Cingulate Cortex Volume in Bipolar I Disorder
  123. Neuropsychiatry and neurophilosophy
  124. Is Deep Brain Stimulation a Form of Psychosurgery?
  125. An agenda for neuropsychiatry as a 21st century discipline
  126. Transcranial magnetic stimulation for the deficit syndrome of schizophrenia
  127. A sham-controlled trial of the efficacy and safety of twice-daily rTMS in major depression
  128. Assessment of complex mental activity across the lifespan: development of the Lifetime of Experiences Questionnaire (LEQ)
  129. The Brain Reserve Hypothesis, Brain Atrophy and Aging
  130. Response to Yucel and MacQueen's letter to the editor
  131. P1–244: Brain reserve: The impact of complex mental activity on dementia incidence, cognitive decline and hippocampal structure and function
  132. Causes and Diagnosis of Alzheimers Disease: A Proteomics Approach
  133. Brain reserve and cognitive decline: a non-parametric systematic review
  134. Gray matter reduction is correlated with white matter hyperintensity volume: A voxel-based morphometric study in a large epidemiological sample
  135. Differential Effects of Transcranial Magnetic Stimulation of Left and Right Posterior Parietal Cortex on Mental Rotation Tasks
  136. Dementia: New Projections and Time for an Updated Response
  137. Chronic repetitive transcranial magnetic stimulation is antidepressant but not anxiolytic in rat models of anxiety and depression
  138. Sex and symmetry differences in hippocampal volumetrics: Before and beyond the opening of the crus of the fornix
  139. An emotional Stroop functional MRI study of euthymic bipolar disorder
  140. Brain reserve and dementia: a systematic review
  141. Frequency and clinical, neuropsychological and neuroimaging correlates of apathy following stroke – the Sydney Stroke Study
  142. Homocysteine and brain atrophy
  143. Obsessive–Compulsive Behaviour: A Disorder of Decision-Making
  144. Obsessive-compulsive behaviour: a disorder of decision-making
  145. Periodic limb movements and other movement disorders in sleep: Neuropsychiatric dimensions
  146. A rating scale for neuroleptic malignant syndrome
  147. Transcranial magnetic stimulation for the deficit syndrome of schizophrenia: A pilot investigation
  148. Neuroleptic-induced Movement Disorders: An Overview
  149. NMS Rating Scale
  150. Animal Models of Drug-Induced Akathisia
  151. Homocysteine, cerebrovascular disease and brain atrophy
  152. P1-004 The Sydney stroke study: a controlled study of the progression of cognitive and functional impairment over one year
  153. Cognitive generation of affect in hypomania: an fMRI study
  154. Early Extrapyramidal Side-Effects as Risk Factors for Later Tardive Dyskinesia: A Prospective Study
  155. Effect of white matter hyperintensities on cortical cerebral blood volume using perfusion MRI
  156. Homocisteína e transtornos psiquiátricos
  157. Magnetic resonance spectroscopy in cognitive research
  158. Quantification of hemorphins in Alzheimer's disease brains
  159. Geriatric psychiatry: is the jury still out on the cognitive effects of homocysteine and one-carbon metabolism?
  160. Memory training alters hippocampal neurochemistry in healthy elderly
  161. Memory training alters hippocampal neurochemistry in healthy elderly
  162. Psychotic disorder and traumatic brain injury
  163. Homocysteine in neuropsychiatric disorders of the elderly
  164. Novel physical treatments for the management of neuropsychiatric disorders
  165. Schizophrenia-like illness in velo-cardio-facial syndrome
  166. Citalopram-Clonazepam combination for primary depersonalizationdisorder: a case report
  167. Magnetic Resonance Spectroscopy and its Applications in Psychiatry
  168. The prolongation of QTc-interval by thioridazine
  169. The Ageing Brain: A Symposium an Introduction
  170. Stimulus Intensity in Transcranial Magnetic Stimulation (TMS) Studies
  171. Schizophrenia-Like Psychosis and Epilepsy: The Status of the Relationship
  172. Reply to Dr Lee
  173. Vascular dementia as a frontal subcortical system dysfunction
  174. How High a Dose of Stimulant Medication in Adult Attention Deficit Hyperactivity Disorder?
  175. The Current Status of Tardive Dyskinesia
  176. Hippocampus and amygdala volumes in elderly schizophrenic patients as assessed by magnetic resonance imaging
  177. Vascular Dementia
  178. Vascular Dementia: An Australian Perspective
  179. An Electroencephalographic Investigation of Late-Onset Schizophrenia
  180. Reliability and validity of ratings of signal hyperintensities on MRI by visual inspection and computerised measurement
  181. Electroconvulsive Treatment of Neuroleptic Malignant Syndrome: A Review and Report of Cases
  182. Mid-sagittal anatomy in late-onset schizophrenia
  183. Attention deficit hyperactivity disorder in adults
  184. Book Review: Organic Psychiatry: the Psychological Consequences of Cerebral Disorder, 3rd ed.
  185. Correspondence
  186. Effects of specific dopamine D1 and D2 receptor antagonists and agonists and neuroleptic drugs on emotional defecation in a rat model of akathisia
  187. Tardive blepharospasm
  188. Regional cerebral blood flow in late-onset schizophrenia: a SPECT study using 99mTc-HMPAO
  189. The effects of β-adrenoceptor antagonists on a rat model of neuroleptic-induced akathisia
  190. Sixty Years of Psychosurgery: Its Present Status and its Future
  191. Relpy
  192. The audiogenic startle reflex in Tourette's syndrome
  193. Tics Status
  194. A Critique of ‘Organic’ and its Proposed Alternatives
  195. Site and size of lesion and psychosurgical outcome in obsessive-compulsive disorder: a magnetic resonance imaging study
  196. Restlessness: The Anatomy of a Neuropsychiatric Symptom
  197. Clozapine-Induced Increase in Plasma Levels of Soluble Interleukin-2 Receptors-Reply
  198. Clozapine-Induced Neuroleptic Malignant Syndrome
  199. The Identification and Management of Drug-Induced Akathisia
  200. Neuropsychological Outcome from Psychosurgery for Obsessive-Compulsive Disorder
  201. Akathisia and Restless Legs
  202. Epidemiology
  203. References
  204. Foreword
  205. Akathisia: development of the concept
  206. The anatomy of restlessness
  207. Neuroleptic-induced dysphoria
  208. The definition of drug-induced akathisia
  209. Clinical characteristics of tardive and chronic akathisia
  210. Clinical characteristics and diagnosis of acute akathisia
  211. Akathisia due to a general medical condition
  212. Assessment and measurement of akathisia
  213. Aetiology and pathogenesis of akathisia
  214. Treatment of drug-induced akathisia
  215. Restless legs syndrome: clinical features and pathophysiology
  216. Treatment of restless legs syndrome
  217. Summary and recommendations for future research
  218. Haskovec's Akathisie
  219. Prince Henry Hospital Akathisia Scale
  220. Barnes (1989) Akathisia Rating Scale
  221. Hillside Akathisia Scale (version 4)
  222. Letters to the editor
  223. Clinical Characteristics and Predisposing Factors in Acute Drug-Induced Akathisia
  224. Referring a Patient for Psychosurgery?
  225. The Clinical Features of Tourette's Disorder: An Australian Study Using a Structured Interview Schedule
  226. Slowness of movement in melancholic depression
  227. A rating scale for acute drug-induced akathisia: development, reliability, and validity
  228. Research diagnostic criteria for drug-induced akathisia: conceptualization, rationale and proposal
  229. Prince Henry Hospital Akathisia Rating Scale
  230. Intravenous benztropine and propranolol challenges in tardive akathisia
  231. Neuropsychiatry
  232. Intravenous Benztropine and Propranolol Challenges in Acute Neuroleptic-Induced Akathisia
  233. Neuroleptic-induced defecation in rats as a model for neuroleptic dysphoria
  234. Tardive and chronically recurrent oculogyric crises
  235. Vascular dementia
  236. Psychotic Symptoms Preceding Ocular Deviation in a Patient with Tardive Oculogyric Crises
  237. Neuroleptic-induced movement disorders and body iron status
  238. Psychosurgical Treatment of Obsessivecompulsive Disorder
  239. Drug-Induced Movement Disorders in Institutionalised Adults with Mental Retardation: Clinical Characteristics and Risk Factors
  240. To the Editor
  241. Golfers' cramp: Clinical characteristics and evidence against it being an anxiety disorder
  242. The Present Status of Akathisia
  243. Acute drug-induced akathisia is not associated with low serum iron status
  244. Pharmacological characterization of tardive akathisia
  245. Intensive Neurodiagnostic Monitoring in Psychiatry
  246. Whakama: culturally determined behaviour in the New Zealand Maori
  247. Behavioural factors affecting physical health of the New Zealand Maori
  248. Mana, Tapu, Noa: Maori cultural constructs with medical and psycho-social relevance
  249. Preface
  250. Schizophrenia-like psychosis and epilepsy
  251. Friedreich's Ataxia and schizophrenia-like psychosis
  252. Wilson's Disease
  253. Drug treatment of secondary schizophrenia
  254. Plate section
  255. Schizophrenia-like psychosis and traumatic brain injury